Bank of Montreal Can Trims Stock Position in Enovis Co. (NYSE:ENOV)

Bank of Montreal Can reduced its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 83.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,615 shares of the company's stock after selling 32,543 shares during the quarter. Bank of Montreal Can's holdings in Enovis were worth $290,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ENOV. Confluence Investment Management LLC purchased a new position in Enovis in the 4th quarter worth approximately $3,494,000. Geode Capital Management LLC grew its holdings in Enovis by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock valued at $39,678,000 after buying an additional 80,165 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after buying an additional 437 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in Enovis by 19.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company's stock valued at $677,000 after buying an additional 2,518 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Enovis in the fourth quarter worth approximately $437,000. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Trading Down 0.3 %

Shares of NYSE:ENOV traded down $0.11 during midday trading on Friday, reaching $35.01. 890,659 shares of the company's stock were exchanged, compared to its average volume of 751,892. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -15.99 and a beta of 1.86. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. Enovis Co. has a fifty-two week low of $29.32 and a fifty-two week high of $56.43. The firm's 50 day simple moving average is $36.51 and its two-hundred day simple moving average is $41.95.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million during the quarter, compared to analysts' expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. As a group, sell-side analysts forecast that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of Enovis in a report on Wednesday, April 9th.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.